Artemis Therapeutics Announces Issuance Of European Patent For Artemisone For The Treatment Of Viral Infections

NEW YORK, Nov. 28, 2017 /PRNewswire/ — Artemis Therapeutics, Inc. (OTCQB: ATMS), (“Artemis” or the “Company”), a pharmaceutical company developing new therapies to treat life-threatening infectious diseases, today announced the recent issuance by the European Patent Office (EPO) of European Patent No. 2839803 entitled “Methods and Compositions for Treating Viral Infections” covering the Company’s lead product candidate, Artemisone, currently in development for the treatment of malaria and cytomegalovirus (CMV). The European patent will provide intellectual property protection for the Artemisone program in key markets and is expected to expire no earlier than 2033.

“The issuance of this European patent is a significant component of our worldwide intellectual property strategy and augments our existing intellectual property assets such as U.S. patent 9,616,067, ‘Methods and Compositions for Treating Viral Infections’, which was allowed in April of this year,” stated Brian M. Culley, Chief Executive Officer of Artemis. “We believe Artemisone has potential across a broad range of human diseases and the issuance of this patent will provide protection as well as strengthen the commercial opportunities for the development of the program beyond malaria and CMV and into additional viral infectious diseases. We look forward to providing information about those additional indications for Artemisone in the coming months.”

About Artemis Therapeutics

Artemis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of new therapies for the treatment and prevention of severe and life-threatening infectious diseases. The Company’s lead product candidate, Artemisone, is a unique, synthetic artemisinin derivative with potent anti-viral and anti-parasitic properties. The Company currently is evaluating Artemisone for the treatment of p. falciparum malaria and human cytomegalovirus (CMV) infections, including stem cell transplant CMV and congenital CMV. Artemis also plans to evaluate Artemisone for the treatment of additional viral and parasitic diseases. More information is available on the Company’s website: and Twitter: @ArtemisThera.

Forward Looking Statements:

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


Investor Relations

SOURCE Artemis Therapeutics, Inc.

Related Links